Product Description: Minocycline is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect[1][2][3][4][5][6][7].
Applications: Metabolism-sugar/lipid metabolism
Formula: C23H27N3O7
Citations: bioRxiv. 2023 Dec 20./Cell Biosci. 2024 Apr 16;14(1):48./Clin Exp Pharmacol Physiol. 2023 Apr 22./Food Chem Toxicol. 2023 Feb 24;113692./Fundam Res. 2023 Jul 16./Int Immunopharmacol. 2023 Jun 2;120:110347./J Genet Genomics. 2023 Sep 11;S1673-8527(23)00184-4./Pharmacol Res. 2023 Apr 15;106773./Research Square Preprint. 2020 Jun./Toxicol Appl Pharmacol. 2024 Feb 9:484:116859./ACS Omega. March 3, 2022./Adv Funct Mater. 2023 Jul 7./Adv Sci (Weinh). 2025 Jan 30:e2412556./Ann Lab Med. 2021 May 1;41(3):293-301./Behav Brain Res. 2024 Jan 2:114843./Brain Behav Immun. 2020 Oct;89:400-413./Brain Behav Immun. 2021 Jan;91:505-518./Brain Behav Immun. 2021 Jan;91:519-530./Brain Sci. 2023 Mar 19./Cell Rep Methods. 2024 Aug 27:100843./Eur J Pharmacol. 2024 Jun 19:176763./Genes (Basel). 2024 Oct 30;15(11):1400./Int Immunopharmacol. 2024 Nov 3;143(Pt 3):113538./Int J Antimicrob Agents. 2018 Aug;52(2):269-271./iScience. 5 January 2022, 103731./J Clin Microbiol. 2025 Feb 19;63(2):e0148024. /J Dent. 2023 Jul 15;104624./J Ethnopharmacol. 2025 Feb 18:119459./J Neuroimmune Pharmacol. 2024 May 22;19(1):23./J Neuroinflammation. 2018 Aug 30;15(1):245. /Mol Neurobiol. 2021 Jun 29./Nat Commun. 2022 Mar 2;13(1):1116./Neurochem Res. 2017 Oct;42(10):2698-2711. /Neuropharmacology. 2018 Jun;135:223-233./Neuropharmacology. 2020 Jun 15;170:108054./Open Forum Infect Dis. 2024 Oct 11;11(11):ofae611./Oxid Med Cell Longev. 05 Nov 2021./Phytomedicine. 2023 Feb 26;113:154725./PLoS One. 2025 Jan 31;20(1):e0315714./Res Sq. 2024 May 7./Research Square Preprint. 2022 Feb./Research Square Preprint. 2024 Mar 6./Theranostics. 2020 Jan 1;10(1):74-90.
References: [1]Xu L, et al. Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats. BMC Neurol. 2004 Apr 26;4:7./[2]Zhang L, et al. Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine. Prog Neuropsychopharmacol Biol Psychiatry. 2006 Dec 30;30(8):1381-93. /[3]Pourgholami MH, et al. Minocycline inhibits growth of epithelial ovarian cancer. Gynecol Oncol. 2012 May;125(2):433-40./[4]Molina-Hernández M, et al. Antidepressant-like actions of minocycline combined with several glutamate antagonists. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):380-6./[5]Ritchie DJ, et al. A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections. Clin Infect Dis. 2014 Dec 1;59 Suppl 6:S374-80./[6]Ataie-Kachoie P, et al. Minocycline attenuates hypoxia-inducible factor-1α expression correlated with modulation of p53 and AKT/mTOR/p70S6K/4E-BP1 pathway in ovarian cancer: in vitro and in vivo studies. Am J Cancer Res. 2015 Jan 15;5(2):575-88./[7]Hu X, Wu B, Wang X, Xu C, He B, Cui B, Lu Z, Jiang H. Minocycline attenuates ischemia-induced ventricular arrhythmias in rats. Eur J Pharmacol. 2011 Mar 11;654(3):274-9.
CAS Number: 10118-90-8
Molecular Weight: 457.48
Compound Purity: 98.59
Research Area: Cancer; Infection; Metabolic Disease; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease
Solubility: DMSO : 25 mg/mL (ultrasonic)
Target: Antibiotic;Apoptosis;Bacterial;Calcium Channel;HIF/HIF Prolyl-Hydroxylase;MDM-2/p53;Potassium Channel
English
Deutsch
